Life Sciences

Matheson partners provide an update on the life sciences sector, across the key areas of corporate M&A, tax, and regulation, incorporating their outlook for 2019 and the post-Brexit implications for businesses operating in this sector.

Ireland submitted its formal bid on 31 July 2017 for Dublin to become the future location of the European Medicines Agency ("EMA") following Brexit.  The new location must be decided by the heads of government of the Member States and 18 other cities have submitted bids to compete for the agency.  The cities competing with Dublin are Amsterdam, Athens, Barcelona, Bonn, Bratislava, Brussels, Bucharest, Copenhagen, Helsinki, Lille, Malta, Milan, Porto, Sofia, Stockholm,

The European Medicines Agency ( "EMA") is a decentralised agency of the European Union responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU.  In the wake of Brexit, the EMA will be relocated.  Dublin is one of many EU cities bidding for the relocation.  In the first of a series of articles on the impact of Brexit on the life sciences industry, Michael Finn explains the bidd

In the post-Brexit climate, Ireland’s position as an English speaking gateway to one of the world’s largest markets will be even more significant than in the past. Given Ireland’s proximity to one of the world’s largest markets, it is plausible that life sciences and medtech companies may move or plan to move some or all of their operations or business lines to Ireland in order to retain access to the European market.